Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.55 |
| ▸ | CHRNG | P07510 | 1/20 | 0.55 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | CHRND | Q07001 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13425656 | 0.86 | PARP1 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL585998 | 0.84 | PARP1 (0.59) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL29923066 | 0.84 | PARP1 (0.59) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL18068936 | 0.82 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL15007483 | 0.82 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1305879 | 0.82 | SLC6A2 (0.57) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL633367 | 0.81 | CHRNA1 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL30310283 | 0.81 | CHRNA1 (0.58) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL1024046 | 0.81 | SLC6A2 (0.55) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL31070147 | 0.81 | SLC6A2 (0.55) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108863740-B | Preparation method of naphthalenone compound | 南昌航空大学 | 2021-04-02 | — | — | CN | disclosed |
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| EP-2571858-B1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RES TRIANGLE INST (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2571858-B1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RES TRIANGLE INST (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| EP-2419400-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| WO-2010121022-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885CHRNA1 186/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885CHRNA1 186/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A3 3/4885CHRNA1 186/4885 |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | SLC6A2 2472/4885SLC6A3 2683/4885CHRNA1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.